Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Seeking Alpha
ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that higher exposure may drive higher clearance and potential off-treatment remission. ORKA-002 could also deliver deeper efficacy via dual IL-17A/F neutralization with 2 to 3 doses per year. It also taps ORKA into PsA/HS. Lastly, ORKA has a highly liquid balance sheet and trades at reasonable valuation multiples. So, I feel it's a “Buy” at these levels. Catherine Delahaye/DigitalVision via Getty Images Oruka Therapeutics, Inc. ( ORKA ) is an early-stage immunology company that develops therapies for psoriasis and related diseases. ORKA's pipeline contains the biologics ORKA-001 for plaque psoriasis (PsO) and ORKA-002 for PsO, psoriatic arthritis (PsA) and hidradenitis suppurativa (HS). These candidates are designed to have improved efficiency and This article was written by Analyst's Disclosure: I/we have no sto
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.MarketBeat
- Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
- Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001GlobeNewswire
- Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
ORKA
Earnings
- 11/12/25 - Beat
ORKA
Sec Filings
- 1/2/26 - Form 4
- 1/2/26 - Form 144
- 12/19/25 - Form 4
- ORKA's page on the SEC website